S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
NEW HAVEN, Conn. - Trevi Therapeutics, Inc. (NASDAQ: TRVI), a $635 million market cap biopharmaceutical company focused on developing treatments for chronic cough and idiopathic pulmonary fibrosis (IPF), announced today the initiation of a public offering of $100 million in common stock. The company’s stock has shown remarkable strength, delivering a 153% return over the past year according to InvestingPro data. The company also plans to offer underwriters a 30-day option to purchase up to an additional $15 million in shares.
The offering is being managed by a team of book-runners including Morgan Stanley, Leerink Partners, Stifel, and Cantor. The sale of shares is contingent on market conditions, and there is no certainty as to the completion or the specifics of the offering. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt on its balance sheet, and a healthy current ratio of 15.4x.
Trevi’s shares are being offered according to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on June 29, 2023, and declared effective on August 15, 2023. A preliminary prospectus supplement detailing the offering terms is expected to be filed with the SEC.
The company is developing Haduvio™ (oral nalbuphine extended-release), which is under clinical trials for treating chronic cough in patients with IPF, non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). Haduvio aims to target opioid receptors that are key in managing chronic cough. Five analysts have recently revised their earnings expectations upward for the upcoming period, with analyst price targets ranging from $13 to $29 per share, as revealed in InvestingPro’s comprehensive research report, which offers detailed analysis of 1,400+ top stocks.
Trevi cautions that statements in the press release that are not historical facts are forward-looking and subject to risks and uncertainties. These include the uncertainties of market conditions affecting the public offering completion and terms. The company refers to its SEC filings for further discussion of risks.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, and no sales will occur in jurisdictions where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The information in this article is based on a press release statement from Trevi Therapeutics, Inc.
In other recent news, Trevi Therapeutics announced positive topline results from its Phase 2b CORAL clinical trial for Haduvio, aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The trial met its primary endpoint, showing statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. Raymond James analysts reiterated a Strong Buy rating for Trevi Therapeutics, citing the trial’s success and setting a price target of $29.00. They noted that Haduvio’s results position it as a leading treatment in the chronic cough landscape, particularly for IPF-related conditions. Meanwhile, H.C. Wainwright initiated coverage on Trevi with a Buy rating and a $21.00 price target, highlighting the revenue potential of Haduvio, which could exceed $1 billion for refractory chronic cough (RCC) alone. B.Riley analysts also maintained a Buy rating with a $20.00 target, emphasizing the significance of the Phase 2a RIVER trial data for RCC. These developments reflect growing confidence in Trevi’s ability to bring Haduvio to market for chronic cough conditions. Trevi plans to engage with the FDA for a Phase 3 program and explore additional trials for chronic cough in non-IPF interstitial lung disease patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.